Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

Publication | Open Access

DOI Full Paper Access

Citations

References

2025

Year

Melanie J. Davies, Peter van der Meer, Subodh Verma, Shachi Patel, Khaja Chinnakondepalli, Barry A Borlaug, Javed Butler, Dalane W Kitzman, Sanjiv J Shah, Signe Harring,

The Lancet Diabetes & Endocrinology